Iran-Made Anti-Cancer Nano Drugs Save over 7 Million US Dollars of Foreign Currency

With the efforts made to obtain standards, knowledge-based and technological companies in Iran have been able to market important products like anti-cancer drugs and health equipment by using nanotechnology in the health and pharmaceutical industry.

The drugs used for the treatment of breast, lung and pancreas cancers were produced with one-fifth of the price of foreign samples in the country. The nano drug for the treatment of metastasizing ovary cancer was also provided to patients. The mentioned medicines saved seven million dollars for the country.

Among the anti-cancer nano-based drugs mention can be made of Paclinab anticancer drug which is used to treat breast, lung and pancreas cancers. By penetrating into the cancerous tissue, Paclinab prevents the progress of tumor and destroys cancerous tissue.

Also, Sina Doxosome drug is used as an anti-tumor nano drug used for the treatment of metastatic breast cancer, specially in patients who are exposed to or have heart problems. It can also treat advanced ovarian cancer.

In a relevant development in November, a senior Iranian official had announced that the nano-based medication produced by the country’s scientists have saved over $90mln of foreign currency in the past 7 years.

“Based to our assessments, Iran has exported $9mln worth of nano drugs in the past 7 years and the sales of anti-cancer nano drugs inside the country is also estimated at 3,700 billion Rials,” Emad Ahmadvand, the head of the headquarters for the development of nanotechnology affiliated to the Iranian Vice-Presidency for Science, Technology and Knowledge-Based Economy.

He noted that the exported anti-cancer nano drugs include Sina Doxosome, Padynex, and Paclinab.

“Iran's anti-cancer nano drug products have also saved over $90mln of foreign currency in the past 7 years,” Ahmadvand said.

4155/v